<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Depression pharmacotherapy is costly, though widely prescribed by physicians. However, less than half of the patients treated obtain complete remission through therapy with single antidepressant drugs. Some patients exhibit partial or no remission and some patients display treatment intolerance responses. This emphasizes the need to identify novel classes of antidepressants [
 <xref rid="B7-molecules-22-01290" ref-type="bibr" class="xref">7</xref>]. The most frequent side effects of these drugs are due to rapid monoamine concentration increases at the receptor sites. These effects could be summarized as increased anxiety, gastrointestinal and sexual problems and decreased alertness. The challenge for such new antidepressants is to achieve fast antidepressant response, broader efficacy, and fewer adverse effects [
 <xref rid="B7-molecules-22-01290" ref-type="bibr" class="xref">7</xref>].
</p>
